SCHEMBL6092744

SCHEMBL6092744

O=C1C(=Cc2ccc(-c3ccc(C(F)(F)F)cc3)o2)SC(=S)N1Cc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.66
KMT2A Q03164 5/20 0.66
ALDH1A1 P00352 5/20 0.66
MAPT P10636 5/20 0.66
POLB P06746 5/20 0.66
RECQL P46063 3/20 0.66
MCL1 Q07820 3/20 0.66
TDP1 Q9NUW8 2/20 0.66
NPSR1 Q6W5P4 2/20 0.66
EIF4E P06730 1/20 0.66
EIF4G1 Q04637 1/20 0.66
THRB P10828 1/20 0.66
LMNA P02545 3/20 0.63
ALOX12 P18054 2/20 0.63
ENPP2 Q13822 1/20 0.63
EP300 Q09472 1/20 0.60
CREBBP Q92793 1/20 0.60
SYK P43405 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.57
MAP3K5 Q99683 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6092742 1.00 MEN1 (0.66) MEN1KMT2AALDH1A1MAPTPOLB
SCHEMBL3132328 0.90 MAPT (0.73) MEN1KMT2AALDH1A1MAPTPOLB
SCHEMBL3132319 0.90 MAPT (0.73) MEN1KMT2AALDH1A1MAPTPOLB
SCHEMBL3132334 0.90 MAPT (0.73) MEN1KMT2AALDH1A1MAPTPOLB
SCHEMBL3890923 0.90 MAP3K5 (0.70) MEN1KMT2AALDH1A1MAPTPOLB
SCHEMBL3890920 0.90 MAP3K5 (0.70) MEN1KMT2AALDH1A1MAPTPOLB
SCHEMBL8289174 0.90 MAP3K5 (0.70) MEN1KMT2AALDH1A1MAPTPOLB
SCHEMBL19021494 0.87 MEN1 (0.73) MEN1KMT2AALDH1A1MAPTPOLB
SCHEMBL22240435 0.86 MEN1 (0.68) MEN1KMT2AALDH1A1MAPTPOLB
SCHEMBL23145046 0.85 STAT3 (0.76) MEN1KMT2AALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them RIGEL PHARMACEUTICALS, INC. (US) 2006-12-07 US disclosed
EP-1597255-A1 RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Rigel Pharmaceuticals, Inc. (US) 2005-11-23 EP disclosed
WO-2004043955-A1 RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM RIGEL PHARMACEUTICALS, INC. (US) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them UBQLN1, UBQLN2, UBE2G2 MEN1 1562/4885KMT2A 901/4885ALDH1A1 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.